eBook - ePub
Medical Physics
Models and Technologies in Cancer Research
Anna Bajek, Bartosz Tylkowski, Anna Bajek, Bartosz Tylkowski
This is a test
Share book
- 263 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
eBook - ePub
Medical Physics
Models and Technologies in Cancer Research
Anna Bajek, Bartosz Tylkowski, Anna Bajek, Bartosz Tylkowski
Book details
Book preview
Table of contents
Citations
About This Book
Modern cancer research is a high-tech undertaking, overlapping with many fields in the physical sciences. These include nanotechnology, engineering, immunology, and bioinformatics. This book focuses on the science and technology underlying the diagnosis and treatement of cancer. The authors offer insights into technologies including radiotherapy, modelling, and drug encapsulation.
Frequently asked questions
How do I cancel my subscription?
Can/how do I download books?
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
What is the difference between the pricing plans?
Both plans give you full access to the library and all of Perlegoâs features. The only differences are the price and subscription period: With the annual plan youâll save around 30% compared to 12 months on the monthly plan.
What is Perlego?
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, weâve got you covered! Learn more here.
Do you support text-to-speech?
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Is Medical Physics an online PDF/ePUB?
Yes, you can access Medical Physics by Anna Bajek, Bartosz Tylkowski, Anna Bajek, Bartosz Tylkowski in PDF and/or ePUB format, as well as other popular books in Naturwissenschaften & Physik. We have over one million books available in our catalogue for you to explore.
Information
1 Personalized and targeted therapies
Magdalena WiĹniewska
Department of Oncology and Brachytherapy, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, ToruĹ, Poland
Department of Clinical Oncology, Oncology Centre, Bydgoszcz, Poland
MichaĹ WiĹniewski
Outpatient Chemotherapy Department, Oncology Centre, Bydgoszcz, Poland
Marzena A. Lewandowska
Department of Thoracic Surgery and Tumors, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, ToruĹ, Poland
Oncology Centre, Bydgoszcz, Poland
Department of Molecular Oncology and Genetics, Innovative Medical Forum Oncology Centre, Bydgoszcz, Poland
ORCID:https://orcid.org/0000-0002-7360-7810
Ludwik Rydygier Collegium Medicum Nicolaus Copernicus University (UMK CM 2018 WL 103 and UMK CM 2020 WL 183)
This article has previously been published in the journal Physical Sciences Reviews. Please cite as: WiĹniewska, M., WiĹniewski, M., Lewandowska, M. A. Personalized and targeted therapies Physical Sciences Reviews [Online] 2021, 6 DOI: 10.1515/psr-2019-0057
Abstract
Biomarker is defined as indicator of normal or pathogenic biological process or response to an intervention or exposure. There are several categories of biomarkers but predictive biomarkers play the most important role in the treatment of neoplasms. In some cancers there may be more than one potential biomarker, and their identification determines the treatment of the patient. Identification of predictive biomarkers allows the development of novel targeted therapies resulting in tailored treatment. In this chapter we discuss most important predictive biomarkers used in contemporary oncology for which there is approved therapies.
Keywords: biomarker, predictive biomarkers, tailored treatment, targeted therapies,
1.1 Introduction
Biomarkers are critical to the rational development of medical diagnostics and therapeutics [1]. Biomarker is defined as indicator of normal or pathogenic biological process or response to an intervention or exposure, according to Food and Drug Administration â National Institute of Health (FDA-NIH) Working Group [2].
There are several categories of biomarkers according to FDA-NIH classification. Predictive biomarkers can be used to identify response to exposure to a therapy or an environmental agent. The response could be a relief of symptoms, improvement in survival, or an adverse effect [2]. Predictive biomarkers are essential to modern personalized therapy in contemporary oncology and are the topic of this chapter. Other categories of biomarkers according to FDA-NIH classification include diagnostic, prognostic, monitoring, safety and pharmacodynamic biomarkers.
1.1.1 Predictive biomarkers
Predictive biomarkers are the most important in the treatment of neoplastic diseases. Their presence allows predicting in which group of patients the therapy will be effective. In some cancers there may be more than one potential biomarker, and their identification determines the treatment of the patient. Table 1.1 represents the broad range of biomarkers, which are analyzed in nonâsmall cell lung cancer to qualify patient for appropriate therapy. There are also biomarkers whose presence is associated with the effectiveness of a given therapy regardless of the type of tumor (so-called organ-independent biomarkers), examples of such biomarkers are mutations in the NTRK or high levels of MSI. In this chapter, predictive biomarkers for which there are approved therapies in the treatment of solid tumors will be discussed.
Disease | Biomarker | Drug |
---|---|---|
Non-small cell lung cancer | EGFR | Erlotinib |
Gefitinib | ||
Osimertinib | ||
Afatinib | ||
Dacomotinib | ||
ALK | Crizotinib | |
Ceritinib | ||
Lorlatinib | ||
Alectinib | ||
Brigantinib | ||
ROS1 | Crizotinib | |
Ceritinib | ||
Lorlatinib | ||
Alectinib | ||
Brigantinib | ||
BRAF | Dabrafenib | |
Vumurafenib | ||
MEK | Capmatinib | |
RET | Selpercatinib | |
PD-L1 | Pembrolizumab | |
NTRK | Entrectinib | |
Larotrektinib | ||
No biomarker | Chemotherapy |
1.1.2 Diagnostic biomarker
Diagnostic biomarker is used as an indicator of a presence of a disease or condition to assess a subtype of the disease, e.g. profiling of gene expression may be used to distinguish subgroups of patients with diffuse large B-cell lymphoma and different gene signatures of malignant cells. Another example of diagnostic biomarker could be measurement of glomerular filtration rate [GFR] in diagnosis of patients with chronic kidney disease [3, 4].
1.1.3 Monitoring biomarker
Monitoring biomarker is an indicator of disease or medical condition status. It may also indicate an effect of a drug of environmental factor. Examples of monitoring biomarkers are prostate-specific antigen (PSA) in patients with prostate cancer or cancer antigen 125 (CA 125) in patients with ovarian cancer. Both biomarkers are used to assess disease status or burden [5, 6].
1.1.4 Risk (screening) biomarkers
Risk (screening) biomarkers indicate the potential for developing a disease or medical condition in an individual who does not currently have clinically apparent disease or the medical condition. Example of risk biomarkers are mutations in genes related to increased risk of developing cancer as BRCA 1/2 (Breast Cancer genes 1 and 2) mutations which are inked with breast cancer [7, 8].
1.1.5 Pharmacodynamic (response) biomarkers
Pharmacodynamic (response) biomarkers indicate a biological response that may be seen in a patient treated with a drug or an environmental factor. Example of a such biomarker is a standardized uptake value (SUV) measured by PET/CT (Positon Emission Tomography/Computed Tomography) with 18-FG-glucose marked contrast, used as a response biomarker when assessing a response in a patients treated with chemotherapy for diffuse large B-cell lymphoma or Hodgkin lymphoma [9, 10].
1.1.6 Safety biomarker
Safety biomarker is measured for determining a risk of toxicity or an adverse effect. It may be assessed after or before an exposure to a drug or an environmental factor. Safety biomarker example cloud be a serum creatinine for monitoring renal toxicity in a patients treated with a potentially...